Abstract
1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have